Cellectis group extends its space in the Biopark building in Paris
The Cellectis pharmaceutical group’s new lease concerns close to 850 sq.m for a six-year firm period. Cellectis is extending its presence in the Biopark complex to nearly 5,500 sq.m, reflecting its robust development and business growth.
This lease takes the total space relet with the two biopharmaceutical groups Cellectis and Parexel in Biopark up to nearly 3,500 sq.m, following the previous tenant’s departure, representing almost 85% of the space initially vacated during the first half of the year.
These transactions also show positive reversion, confirming the appeal and good performance of rental markets in the Paris Region’s central sectors and Paris City in particular.
To safeguard its communications, Gecina certifies its contents with Wiztrust. You can check their authenticity at www.wiztrust.com.
Contacts
-
-
Julien Landfried
Executive Director Communications, Public Affairs and Brand
